TerThera's GMP Certification for Terbium-161: A Milestone in Oncology
In a groundbreaking development for cancer therapy, TerThera has successfully achieved GMP (Good Manufacturing Practices) certification for its innovative Terbium-161 product. This significant milestone not only marks the introduction of the world's first GMP-compliant Terbium-161 NCA (non-carrier-added), but also establishes a new benchmark in the commercial-scale production of this promising radionuclide.
Enhancing Clinical Access with High Standards
The successful implementation of European Good Manufacturing Practices ensures that TerThera's Terbium-161 complies with the highest quality and safety standards necessary for clinical trials and patient care. This development is particularly crucial as it effectively lowers regulatory barriers, accelerating the immune pathway for new therapies. Hospitals, clinicians, and researchers now have immediate access to this next-generation therapeutic radionuclide, enhancing options for disease management.
Transformative Impact on Cancer Treatment
Terbium-161 is distinct as a no-carrier-added, neutron-activated radionuclide, designed specifically for Radio Ligand Therapy (RLT). It features a robust emission of Auger electrons and a high Linear Energy Transfer (LET). With chemical properties that align closely with established radiolanthanides, this radionuclide holds immense potential to effectively target both primary tumors and (micro) metastases. When used in conjunction with established targeting vectors such as PSMA, SST, and FAPI analogues, Tb-161 shows significant bioequivalence while markedly increasing absorbed doses across all lesions. This offers exciting new treatment options and strategies within cancer healthcare, thereby improving overall disease control and potentially countering the effects of radio-resistant cancer.
Leadership Perspective: A Vision for Global Reach
Philippe van Overeem, CEO of TerThera, expressed his enthusiasm regarding this remarkable achievement: "This milestone is more than a regulatory achievement—it's a leap forward in our mission to bring Terbium-161 to patients worldwide. GMP Terbium-161 is now a clinical reality, and this is just the beginning. We are actively constructing a large-scale production facility to meet the growing global demand and expand access to this promising radionuclide for optimized cancer treatments." TerThera's commitment to revolutionizing the landscape of radiopharmaceuticals showcases its leadership in the field of precision oncology.
About TerThera B.V.
TerThera, based in The Netherlands, is dedicated to radionuclide production and has assembled a highly skilled team with decades of experience in the nuclear medicine industry. They are passionately committed to bringing the cutting-edge radionuclide Terbium-161 (Tb-161) into clinical practice. To respond to the increasing demand for radionuclides in RLT, TerThera is in the process of developing a global platform, which includes GMP production facilities in regions like Europe, the USA, and Asia.
Frequently Asked Questions
What is GMP certification?
GMP certification ensures that products are consistently produced and controlled according to quality standards, minimizing risks involved in pharmaceutical production.
How does Terbium-161 work in cancer treatment?
Terbium-161 targets cancer cells through Radio Ligand Therapy, utilizing its unique properties to enhance treatment efficacy against tumors and metastases.
Who is the CEO of TerThera?
Philippe van Overeem is the CEO of TerThera, leading the company's mission to advance radionuclide-based therapies.
Where is TerThera headquartered?
TerThera is headquartered in The Netherlands and is focused on global radionuclide production.
What are the future plans for TerThera?
TerThera aims to expand its production capabilities and enhance global access to Terbium-161, focusing on the development of large-scale facilities.
